The company's consolidated net profit was 1.34 billion rupees (nearly $16 million) for the quarter ended Dec. 31, compared with 1.06 billion rupees a year earlier.

The Mumbai-based company's sales have benefitted from a series of acquisitions involving companies with portfolios of cardiovascular and ophthalmology drugs. Moreover, sales were boosted by new product launches.

J B Chemicals, known for manufacturing generic drugs and herbal lozenges used to soothe irritated throats, said its revenue from operations rose 6.6% to 8.45 billion rupees.

Revenue growth was fuelled by a 14% increase in its domestic business, its largest market, and a 6% rise in overseas business, including the Russian and South African markets.

The company did not give a region-wise revenue break up.

J B Chemicals' results follow those of larger generic drugmakers such as Cipla, Dr Reddy's and Sun Pharma, all of which beat their third-quarter profit estimates on robust U.S. sales.

($1 = 83.0429 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Dhanya Ann Thoppil)